Boston Scientific (BSX) Tops Q4 EPS by 4c, Beats on Revenue; Offers Guidance

Boston Scientific (NYSE: BSX) reported Q4 EPS of $0.55, $0.04 better than the analyst estimate of $0.51. Revenue for the quarter came in at $3.73 billion versus the consensus estimate of $3.6 billion.

The company estimates net sales growth for the full year 2024, versus the prior year period, to be in a range of approximately 8.5 to 9.5 percent on a reported basis, and approximately 8 to 9 percent on an organic basis. Full year organic net sales guidance excludes the impact of foreign currency fluctuations and net sales attributable to acquisitions and divestitures for which there are less than a full period of comparable net sales. The company estimates EPS on a GAAP basis in a range of $1.38 to $1.42 and estimates adjusted EPS, excluding certain charges (credits), of $2.23 to $2.27.

The company estimates net sales growth for the first quarter of 2024, versus the prior year period, to be in a range of approximately 7.5 to 9.5 percent on a reported basis, and approximately 7 to 9 percent on an organic basis. First quarter organic net sales guidance excludes the impact of foreign currency fluctuations and net sales attributable to acquisitions and divestitures for which there are less than a full period of comparable net sales. The company estimates EPS on a GAAP basis in a range of $0.29 to $0.31 and estimates adjusted EPS, excluding certain charges (credits), of $0.50 to $0.52.

For earnings history and earnings-related data on Boston Scientific (BSX) click here.

You May Also Be Interested In

• Ennis (EBF) Reports In-Line Q1 EPS
• Micron Technology (MU) PT Raised to $1,550 at Needham
• Accenture (ACN) Tops Q3 EPS by 8c, Misses on Revenue; Offers FY26 EPS Guidance